Table 3: Worst toxicity for 42 patients with advanced gastro-esophageal adenocarcinoma treated receiving DOX.
|
Hematologictoxicity |
Grade II n (%) |
Grade III |
Grade IV |
|
Neutropenia |
3 (7%) |
10 (24%) |
10 (24%) |
|
Thrombocytopenia |
0 |
0 (0%) |
0 (0%) |
|
Febrile neutropenia |
- |
13 (31%) |
1 (2%) |
|
Non-hematologic toxicity |
Grade II |
Grade III |
Grade IV |
|
Nausea |
8 (19%) |
3 (7%) |
0 |
|
Diarrhoea |
6 (14%) |
6 (14%) |
0 |
|
Vomit |
4 (10%) |
1 (2%) |
0 |
|
Neuropathy |
13 (31%) |
7 (17%) |
0 |
|
Fatigue |
23 (55%) |
5 (12%) |
0 |
|
Nail toxicity |
13 (31%) |
5 (12%) |
- |
|
HFS |
8 (19%) |
3 (7%) |
|
|
Anorexia |
3 (7%) |
2 (5%) |
|
In addition one patient had pulmonary embolism after the 6th cycle of DOX.